Medical research lab
Trusted by 2,500+ Clinicians Worldwide

Revolutionary Peptide Therapies for Optimal Patient Outcomes

FDA-monitored compounds and advanced weight management solutions designed exclusively for healthcare providers

Pharmaceutical Grade
Peer-Reviewed
Lab-Verified
THERAPEUTIC SOLUTIONS

Evidence-Based Medical Treatments

Pharmaceutical-grade compounds supported by clinical research and trusted worldwide.

FDA-Approved (2017)
Semaglutide (Ozempic)
GLP-1 Agonist • Weekly Injection
★★★★½ (SUSTAIN Trials)

Semaglutide (Ozempic®)

Indications: T2DM, CVD risk reduction
Avg. A1C Reduction: 1.5-1.8%
Weight Loss: 4-6% (T2DM patients)
Dosing: 0.25mg → 0.5mg → 1mg weekly
⚠️ Box Warning: Thyroid C-cell tumors

FDA-Approved (2021)
Semaglutide (Wegovy)
GLP-1 Agonist • Weight Management
★★★★★ (STEP Trials)

Semaglutide (Wegovy®)

Indications: Chronic weight management
Avg. Weight Loss: 14.9% at 68 weeks
Dosing: 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg
Eligibility: BMI ≥30 or ≥27 + comorbidity
⚠️ Nausea in 44% patients

FDA-Approved (2022)
Tirzepatide (Mounjaro / Zepbound)
GIP/GLP-1 Dual Agonist • Weekly
★★★★★ (SURMOUNT Trials)

Tirzepatide (Mounjaro® / Zepbound®)

Indications: T2DM (Mounjaro), Obesity (Zepbound)
Weight Loss: 15-22.5% (72 weeks)
Dosing: 2.5mg → 5mg → 7.5mg → 10mg → 15mg
Key Advantage: Dual hormone action
⚠️ Avoid with history of pancreatitis

Phase 3 Trials (2024)
Retatrutide (LY-3437943)
GLP-1/GIP/Glucagon Triple Agonist
★★★★☆ (TRIUMPH Trials)

Retatrutide (LY-3437943)

Potential: 24% weight loss in early studies
Mechanism: Triple hormone activation
Phase 3: Expected completion 2025
Differentiator: Glucagon component for metabolism
⚠️ Investigational - Not FDA Approved

Research Peptide
BPC-157
15-Amino Acid Peptide • Experimental
★★★★☆ (Preclinical Data)

BPC-157

Proposed Mechanisms:
• Angiogenesis promotion
• Tendon/ligament healing
• GI mucosa protection
Status: Not FDA-approved
⚠️ For research purposes only

Research Peptide
TB-500
Thymosin β-4 Fragment • Experimental
★★★★½ (Animal Studies)

TB-500

Proposed Effects:
• Tissue regeneration
• Anti-inflammatory action
• Wound healing acceleration
Status: Not FDA-approved
⚠️ Laboratory research only

*Available under supervised use and under approved dosage alone.

OUR STORY

Pioneers in Metabolic Therapies

For over a decade, MetaboMedica has been at the forefront of peptide research and metabolic solutions.

Scientific Excellence

Founded by leading endocrinologists with 50+ combined years in metabolic research.

Global Impact

Trusted by clinicians in 37 countries with therapies improving 2.1M+ patient lives.

Quality Assurance

FDA, EMA, and PMDA approved facilities with the highest purity standards.

Learn More About Us
MEDICAL INQUIRIES

Information Request Form

Complete this form to receive detailed product information, usage guidelines, and research data for our solutions.

Format: (123) 456-7890 or 123-456-7890
0/500
CLINICAL EDUCATION

Medical Insights & Case Studies

Evidence-based resources and real-world clinical experiences to inform your practice

GLP-1 Medications Clinical Chart
Clinical Review
Endocrinology June 15, 2023

GLP-1 Receptor Agonists: Weight Management Protocols

Comprehensive analysis of dosing strategies, patient selection criteria, and monitoring protocols for optimal outcomes with GLP-1 therapies.

Read Clinical Review
Doctor consulting patient
Case Study
Diabetes Care May 28, 2023

Tirzepatide in Clinical Practice: 12-Month Outcomes

Detailed examination of A1C reduction, weight loss trajectories, and patient adherence patterns from a real-world cohort.

View Case Details
Research lab and peptide therapies
Research Update
Metabolic Health April 10, 2023

Emerging Peptide Therapies: 2025 Clinical Trial Data

Analysis of phase 2/3 trial results for novel peptide compounds targeting obesity and metabolic syndrome.

Explore Research
View All Clinical Resources